Alleviation of systemic manifestations of castleman's disease by monoclonal anti-interleukin-6 antibody

Joseph T. Beck, su Ming Hsu, John Wijdenes, Regis Bataille, Bernard Klein, David Vesole, Katherine Hayden, Sundar Jagannath, Bart Barlogie

Research output: Contribution to journalArticlepeer-review

318 Scopus citations

Abstract

Castleman's disease (angiofollicular lymphoid hyperplasia) is a heterogeneous group of lymphoproliferative disorders of uncertain cause1. Two pathologic types, hyaline vascular and plasma-cell disease, have been recognized. The plasma-cell variant of Castleman's disease may be localized or multicentric. Multicentric disease is a systemic lymphoproliferative disorder characterized by lymphadenopathy, hepatosplenomegaly, and constitutional symptoms. Anemia, hypoalbuminemia, and hypergammaglobulinemia are also common. Interleukin-6, a cytokine with pleiotropic effects on the immune system, hematopoiesis, and acute-phase reactions, is a putative growth factor in multiple myeloma and may also be central to the pathophysiology of Castleman's disease27. Administration of a murine anti-interleukin-6 monoclonal.

Original languageEnglish
Pages (from-to)602-605
Number of pages4
JournalNew England Journal of Medicine
Volume330
Issue number9
DOIs
StatePublished - 3 Mar 1994
Externally publishedYes

Fingerprint

Dive into the research topics of 'Alleviation of systemic manifestations of castleman's disease by monoclonal anti-interleukin-6 antibody'. Together they form a unique fingerprint.

Cite this